HomeTechnology TransferTechnologiesRNA Editing Enzyme and Methods of Use Thereof
Technology Transfer

RNA Editing Enzyme and Methods of Use Thereof

Inventor(s)
Tech ID
NK-9480
Key Words
Diagnostic, glutamate, immunoassay, neurological disease, psychiatric disease, research tool, screening, serotonin, Therapeutic
Applications and Advantages

Wistar researchers have identified an ADAR protein that may be useful for the development of diagnostics and therapeutics for managing conditions associated with glutamate-gated ion channel defects or serotonin receptor defects. Potential applications of ADAR include:

  • Screening assays for novel central nervous system therapeutic agents,
  • Diagnostic assays, using anti-ADAR antibodies developed at Wistar,
  • Generation of therapeutic agents for stroke, depression, schizophrenia or substance abuse.
Intellectual Property Status

U.S. Patent Nos. 5,643,778; 5,677,428 and 5,763,174.

Licensing Opportunity

This technology is available for licensing for development of diagnostic or therapeutic agents. Additionally, antibodies to ADAR are available for licensing for research use.